Englander Institute for Precision Medicine

Preclinical Models & Drug Screens

The Englander Institue's lab has developed miniature 3D cellular structures, called organoids. that imitate a patient’s tumor. These models are used to predict drug resistance and help direct the best line of therapy with the assistance of the EIPM High-Throughput Drug Screening Platform. 

Imitating Your Tumor to Find the Best Therapy 

Our diverse biobank of patient-derived organoid models are a valuable resource for researchers and clinicians. In addition to banking tumor organoids, our team has assembled an impressive drug compound screening platform to better understand and treat each patient's disease.

To develop preclinical models and begin high throughput drug screening please contact ipminfo@med.cornell.edu

Benjamin Hopkins, PhD
Director, Ex vivo models

Jenna Moyer
Platform Manager - Ex vivo models

Ilkay Us
HTDS Core Administrator

Englander Institute for Precision Medicine

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021